… cells specific for SARS-CoV-2 Spike WT and variants of concern from vaccinated subjects …
antibodies able to block SARS-CoV-2 variants of concern and partially neutralizes SARS-CoV-…

… Spike (S) protein of SARS-CoV-1, which had the ability to escape from neutralizing antibodies,
became the dominant variant as the outbreak proceeded. For SARS-CoV-2, the mutation …

… I converting enzyme 2) and many neutralising antibodies bind. While NTD mutations appear
… points enabling spike to escape neutralising antibodies while maintaining or even gaining …

… The RBD is the major target of neutralizing antibodies (NAbs) induced by SARS-CoV-2
infection, with residual activity directed at the NTD [50]. Three of spike mutations are in the NTD (…

… cell entry by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were being …
eliciting neutralizing antibodies that block spike and therefore prevent the ability of SARS-CoV-…

… on the still controversial question of how efficiently antibodies can bind and neutralize
SARS-CoV-2 variants of concern. The presence of large titers of IgG antibodies within the saliva of …

… SARS-CoV-2 infection 7,8,9,10,11,12 , information on the durability and long-term cross-reactivity
of the antibody response against SARS-CoV-2 … the antibody response in SARS-CoV-2-…

… There was enrichment for the mutation T478K or T478R when SARS-CoV-2 was subjected
to weak neutralizing antibodies, which indicates this mutation may lead to antibody escape. …

… Antibody-based antiviral therapies largely work by neutralizing virions. … of antibody-based
therapies, the mechanism of action of mAbs, and the mutation-prone nature of SARS-CoV-2. …

… antibodies and underscores the need for additional antibody-based … antibodies targeting
SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus …